The problems and pitfalls in systemic lupus erythematosus drug discovery

Expert Opinion on Drug Discovery

Volumn 11, Issue 6, 2016, Pages 525-527

  Rodríguez Pintó, Ignasi ^a   Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

clinical trial; drug approval; epidemiologic methods; pragmatic trial; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; BELIMUMAB; MYCOPHENOLATE MOFETIL; PLACEBO; RITUXIMAB;

CLINICAL PRACTICE; CREATININE URINE LEVEL; DRUG DEVELOPMENT; EDITORIAL; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL TRIAL (TOPIC); DRUG DESIGN; PATIENT SELECTION; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT SELECTION;

EID: 84965007408     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1181056     Document Type: Editorial

References (16)

1. D.J.Wallace The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol. 2015;11(10):616–620. doi:10.1038/nrrheum.2015.86.
2. I.Rodriguez-Pintó, G.Espinosa, R.Cervera. Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. Clin Investig. 2015;5(6):561–571. doi:10.4155/cli.15.16.
3. R.Furie, M.Petri, O.Zamani, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi:10.1002/art.30613.• Second pivotal study for the development of belimumab.
4. B.H.Rovin, R.Furie, K.Latinis, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–1226. doi:10.1002/art.34359.
5. R.Furie, K.Nicholls, -T.-T.Cheng, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–389. doi:10.1002/art.v66.2.
6. D.J.Wallace, W.Stohl, R.A.Furie, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–1178. doi:10.1002/art.24699.
7. S.V.Navarra, R.M.Guzmán, A.E.Gallacher, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi:10.1016/S0140-6736(10)61354-2.• First pivotal study for the development of belimumab.
8. S.Y.Yuen, J.E.Pope. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford). 2008;47(9):1367–1372. doi:10.1093/rheumatology/ken230.
9. R.Cervera, M.A.Khamashta, J.Font, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–124. doi:10.1097/00005792-199303000-00005.•• Largest descriptive systemic lupus erythematosus clinical study conducted so far.
10. R.Cervera, M.A.Khamashta, J.Font, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308.•• Largest follow-up study on systemic lupus erythematosus clinical study published so far.
11. M.Petri, N.Kasitanon, -S.-S.Lee, et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008;58(6):1784–1788. doi:10.1002/art.23794.
12. A.Sinclair, G.Appel, M.A.Dooley, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007;16(12):972–980. doi:10.1177/0961203307084712.
13. M.Dall’Era, M.G.Cisternas, D.E.Smilek, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305–1313. doi:10.1002/art.39026.
14. R.Furie, K.Toder, E.Zapantis. Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Semin Nephrol. 2015;35(5):509–520. doi:10.1016/j.semnephrol.2015.08.012.•• Interesting review on the lessons learned from previous clinical trials.
15. T.Jónsdóttir, A.Zickert, B.Sundelin, et al. Long-term follow-up in lupus nephritis patients treated with rituximab–clinical and histopathological response. Rheumatology (Oxford). 2013;52(5):847–855. doi:10.1093/rheumatology/kes348.
16. R.A.Lew, M.H.Liang, G.Doros. Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier. Arthritis Res Ther. 2015;17:345. doi:10.1186/s13075-015-0874-0.